NUVB has been the subject of several other research reports. HC Wainwright began coverage on Nuvation Bio in a research report on Wednesday, May 4th. They issued a buy rating and a $14.00 target price for the company. Wedbush decreased their target price on Nuvation Bio from $17.00 to $5.00 and set an outperform rating for the company in a research report on Monday.
Nuvation Bio Stock Down 8.0 %
NUVB opened at $2.29 on Tuesday. The firm has a market cap of $501.65 million, a PE ratio of -5.45 and a beta of 0.46. The business has a fifty day simple moving average of $3.49 and a 200-day simple moving average of $5.01. Nuvation Bio has a fifty-two week low of $2.48 and a fifty-two week high of $10.45.
Institutional Investors Weigh In On Nuvation Bio
A number of large investors have recently added to or reduced their stakes in NUVB. Allspring Global Investments Holdings LLC acquired a new position in shares of Nuvation Bio during the fourth quarter worth approximately $463,000. Rhumbline Advisers lifted its holdings in shares of Nuvation Bio by 187.3% during the fourth quarter. Rhumbline Advisers now owns 150,477 shares of the company’s stock worth $1,279,000 after buying an additional 98,100 shares during the last quarter. EDBI Pte Ltd acquired a new position in shares of Nuvation Bio during the fourth quarter worth approximately $10,799,000. Kingdon Capital Management L.L.C. acquired a new position in shares of Nuvation Bio during the fourth quarter worth approximately $3,600,000. Finally, SG Americas Securities LLC lifted its holdings in shares of Nuvation Bio by 1,763.1% during the fourth quarter. SG Americas Securities LLC now owns 538,852 shares of the company’s stock worth $4,580,000 after buying an additional 509,929 shares during the last quarter. Institutional investors own 70.88% of the company’s stock.
About Nuvation Bio
Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer.
- Get a free copy of the StockNews.com research report on Nuvation Bio (NUVB)
- AMD Q2 Earnings Beat Expectations Significantly, Is AMD A Buy?
- 3 Health Care Stocks in Great Financial Health
- Amazon Names Itself A Top Stock Of Q3 Contender
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Market Fundamentals Drive Results For The Williams Companies
Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.